Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone971-228-0709
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$260,000.00
Profitability
Miscellaneous
Employees6
Next Earnings DateN/A
OptionableNot Optionable
Entia Biosciences (OTCMKTS:ERGO) Frequently Asked Questions
What is Entia Biosciences' stock symbol?
Entia Biosciences trades on the OTCMKTS under the ticker symbol "ERGO."
Has Entia Biosciences been receiving favorable news coverage?
News stories about ERGO stock have been trending neutral on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Entia Biosciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Entia Biosciences.
Who are some of Entia Biosciences' key competitors?
Who are Entia Biosciences' key executives?
Entia Biosciences' management team includes the folowing people:
- Dr. Marvin S. Hausman M.D., Chairman and Chief Science & Technology Officer (Age 78)
- Mr. Timothy A. Timmins, CEO & Pres (Age 62)
- Mr. Elliot A. L. Shelton Esq., Sec. and Director (Age 69)
- William Meyer, Head of Production
How do I buy shares of Entia Biosciences?
Shares of ERGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Entia Biosciences' stock price today?
One share of ERGO stock can currently be purchased for approximately $0.0090.
How big of a company is Entia Biosciences?
What is Entia Biosciences' official website?
How can I contact Entia Biosciences?
Entia Biosciences' mailing address is 13565 SW TUALATIN-SHERWOOD ROAD. SUITE 800, SHERWOOD OR, 97140. The biotechnology company can be reached via phone at 971-228-0709.
MarketBeat Community Rating for Entia Biosciences (OTCMKTS ERGO)
MarketBeat's community ratings are surveys of what our community members think about Entia Biosciences and other stocks. Vote "Outperform" if you believe ERGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
